Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
|Articles|January 21, 2014

AG Mednet Introduces Remote, Non-DICOM File Systems for Clinical Trials, Improves Data Quality

AG Mednet has announced the availability of new capabilities to enable sponsors, CROs and core laboratories to take delivery of electronic trial data

AG Mednet has announced the availability of new capabilities to enable sponsors, CROs and core laboratories to take delivery of electronic trial data into configurable file structures residing either locally or in any of their network shares. This functionality provides higher-quality data and less delays, making it the most efficient method to collect and transfer Holter data, spectral-domain OCT and newer modalities not yet conforming to the DICOM standard.

Now, meta-data can be assigned to non-DICOM modalities and used for configuring, on a per-study basis, structured directories with explicit hierarchies based on the acquired meta-data. This is especially important for:

  • Sites participating in AG Mednet-based clinical trials. The assembly and delivery of imaging submissions remains consistent across both DICOM and non-DICOM data sets;

  • Sponsors, CROs and core laboratories. Non-DICOM modalities are delivered to a file system-based infrastructure, while DICOM modalities are delivered either to a standard DICOM environment, or the same file system-based infrastructure.

“In combination with our ability to tag and deliver this data not just to DICOM repositories but also to local file systems, we’re providing cardiovascular trials, as well as projects requiring specialized non-DICOM modalities, with a way to ensure higher quality and less delays than other methods,” said Abraham Gutman, President & CEO of AG Mednet.

For more information about AG Mednet, please visit www.agmednet.com.


Related to this article

What Needs to Happen Beyond the Clinical Trial Modernization Act
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.